Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
about
The evaluation and treatment of graves ophthalmopathyPlatelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatmentGraves' ophthalmopathyNuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?Increased generation of fibrocytes in thyroid-associated ophthalmopathy.A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.Immunopathogenesis of thyroid eye disease: emerging paradigmsRisk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.Graves' ophthalmopathy as an indication increased the risk of hypoparathyroidism after bilateral thyroidectomyMeta-analysis of association between the +49A/G polymorphism of cytotoxic T-lymphocyte antigen-4 and thyroid associated ophthalmopathy.Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathyGraves' ophthalmopathy: a review of immunogenetics.TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy.Determinants of extraocular muscle volume in patients with graves' disease.Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective StudyDelineating the autoimmune mechanisms in Graves' diseaseThyroid-associated ophthalmopathy: a practical guide to classification, natural history and management.Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.Development of a Novel Thyroid Function Fluctuated Animal Model for Thyroid-Associated OphthalmopathyRisk factors for development or deterioration of Graves' ophthalmopathyImmunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptorRadioiodine thyroid ablation in graves' hyperthyroidism: merits and pitfalls.TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves diseasePathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatmentCorrelation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathyPathogenesis of Graves' ophthalmopathy: the role of autoantibodies.Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassayDiagnosis, Follow-Up and Treatment Results in Thyroid OphthalmopathyEvidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.Emerging pharmacotherapy for treatment of Graves' diseaseGraves' orbitopathy: imperfect treatments for a rare disease.Medical management of thyroid eye disease.Age differences in clinical manifestation and prognosis of thyroid eye disease.Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
P2860
Q26862144-AD1743F1-0BE4-4199-8872-2DF1922E10E7Q27005680-8C2E423E-CE3A-4231-A35D-EF172A20244FQ28274196-4AC9DB04-E6BE-4404-B63B-4575324EC977Q28730668-486B10A4-9A4D-4672-AA15-D19199E521C8Q33348029-4817B8C3-1B94-4F67-9FB4-52444FD1AEC6Q33586738-F54E66A1-1895-487D-ADEE-000E687F8A07Q33707825-BA6A3C33-705C-4558-A215-516493F2069CQ33789467-5AFF8B9E-71E2-46C1-863C-1343143C9A69Q34200995-4A1BC7F4-F7DA-4830-B240-89F6DAAAB00CQ34394088-B17D5135-6C99-4E0F-BC8A-32EC20460BC6Q34782210-769A543D-5FFA-41F9-AD2A-1AE8B8E0BA5EQ35206790-3B0A80CC-F795-4B65-AD34-F653F10042E7Q35547833-9564447E-0DFA-4A62-A618-32C11E635873Q35593232-EBF28113-231D-4FCF-8EA2-52FC76BAF7A6Q35731002-9C3549EB-2048-440C-9B40-E870178CB945Q35785116-2679F235-4010-4CB1-84BA-886DAFFAE41CQ35837773-CC886154-E9EF-48A3-BDAC-21EF5577F43EQ35843186-88B945AD-6040-4829-8527-7E7EC3672F6DQ35857020-144000FD-7D2A-4F83-B208-8885D809FF05Q35866148-8C0DA4ED-3A67-4ACD-BC40-6C5EB64E5C3BQ35904885-B9F8DBFA-3A6A-4A70-B8CA-94D166190A42Q35922627-BAB208EA-F314-408E-A519-1050E694945CQ35975724-0B42C50E-8827-42F8-AA4C-FDB6BF9C62AFQ35992560-F6BBD80C-7DBB-46CC-922D-0AC8ED92CF53Q36147341-B7538485-690E-48CD-8529-80D073B832D1Q36181924-C6EFBFF4-B818-461E-9F9E-1A264A226850Q36393011-5E4A952C-564C-445B-A5A1-CE68285469B1Q36481812-6C8ADCFC-BD3D-4D45-A36E-82001D6FE552Q36525240-DE646888-CE39-4638-AE29-364C66BB5C93Q36872831-2D9BB64C-D4FE-4090-B32C-FF1D6C83FCF6Q36970632-EB124087-CE2C-4DF6-8A99-5896629543FAQ37017174-5114F92F-9C7C-448A-A1F6-30037EDA7BF7Q37087157-41D0D320-E5A1-4974-BC8B-AA636FD75AC6Q37370486-B3C5465C-0725-45ED-8507-6955B8FE07FEQ37417167-9B060C4E-531E-4E9C-A715-012E0F607E6AQ37515491-8F36024A-6D2F-4A2F-A5BA-AB3363AE0D64Q37582446-E1FF24E0-C1AD-4232-B2DB-3BFF8AA13212Q38130235-3A980F77-8DD3-4A1C-AEB3-29782DD54286Q38582072-26D2042B-1B73-402E-ADD9-F26AB2BB6679Q38633022-3852785B-1C9B-4116-B960-F134BFDB8DD1
P2860
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Association of thyrotrophin re ...... res of Graves' ophthalmopathy.
@en
type
label
Association of thyrotrophin re ...... res of Graves' ophthalmopathy.
@en
prefLabel
Association of thyrotrophin re ...... res of Graves' ophthalmopathy.
@en
P2093
P2860
P1476
Association of thyrotrophin re ...... res of Graves' ophthalmopathy.
@en
P2093
Broenink M
Gerding MN
Prummel MF
Wiersinga WM
van der Meer JW
P2860
P304
P356
10.1046/J.1365-2265.2000.00959.X
P577
2000-03-01T00:00:00Z